ACTRN12617001577303已完成未知
A Phase II trial evaluating exercise for patients with brain cancer - determining the feasibility and safety of an 18-week individualised exercise program .
Haematology & Oncology Clinics of Australia Research Centre Ltd (Trading as Icon Cancer Foundation)0 个研究点目标入组 12 人开始时间: 2017年11月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit(—)
- 性别
- All
入选标准
- •1.People with a diagnosis of primary or recurrent malignant brain tumour (i.e. brain cancer e.g. gliomas (astrocytomas, glioblastomas, oligodendrogliomas, ependymomas and mixed cell type gliomas)). Patients with recurrent brain cancer are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment. .
- •2.Age 18 years or older
- •3.Eastern Cooperative Oncology Group (ECOG) status 0-2.
- •4.Willing and able to comply with all study requirements, including the exercise intervention, timing and/or nature of required assessments.
- •5.Sufficiently fluent in English to fully participate in data collection requirements and comprehend intervention requirements.
- •6.Anticipated survival of a minimum of 12 months, as assessed by the treating clinician (e.g. medical oncologist, radiation oncologist, or surgeon).
- •7.If radiotherapy was received, they are between 12 and 26 weeks post-radiotherapy (receipt of oral chemotherapy during this period is allowed).
- •8.Signed written informed consent.
- •9.Deemed suitable to participate in the study by treating clinician.
排除标准
- •1.Diagnosis of secondary brain cancer, or brain cancer recurrence within the first two years of definitive primary treatment.
- •2.Diagnosis of central nervous system lymphoma.
- •3.History of another malignancy within 2 years prior to registration. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment. Patients with a diagnosis of basal cell carcinoma and squamous cell carcinomas and pre-malignant carcinomas (e.g. in situ) are also eligible.
- •4.Concurrent illness, including severe infection or unstable angina that may jeopardise the ability of the patient to undergo the exercise intervention outlined in this protocol with reasonable safety.
- •5.Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol, as determined by their treating clinician.
研究者
相似试验
尚未招募
不适用
A phase 1 trial of exercise for patients admitted to hospital with acute exacerbation of chronic obstructive pulmonary disease (COPD)Acute exacerbation of COPDRespiratory - Chronic obstructive pulmonary diseaseACTRN12608000605392Clarice Youci Tang30
已完成
2 期
A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLCNL-OMON46669European Thoracic Oncology Platform (ETOP)4
进行中(未招募)
1 期
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RET-rearrangement.EUCTR2017-002063-17-NLETOP (European Thoracic Oncology Platform)44
进行中(未招募)
1 期
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RET-rearrangement.EUCTR2017-002063-17-SIETOP (European Thoracic Oncology Platform)44
进行中(未招募)
1 期
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RET-rearrangement.Advanced stage RET-rearranged NSCLCMedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002063-17-BEETOP (European Thoracic Oncology Platform)14
